Sign in
4

Changes in Ownership

4D Molecular Therapeutics, Inc. Filed Acc 0001193125-26-354313

Chief Legal Officer sold 3,270 shares at an average $12.10 ($39,567)

  • Chief Legal Officer acquired 3,270 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Bizily Scott Chief Legal Officer 2026-08-13 Option exercise 10b5-1 +1,635 $4.14 $6,769 10,252 D: show line 1 in the form
Bizily Scott Chief Legal Officer 2026-08-13 Sale 10b5-1 −1,635 $12.00 $19,620 8,617 D: show line 2 in the form
Bizily Scott Chief Legal Officer 2026-08-17 Option exercise 10b5-1 +1,635 $4.14 $6,769 10,252 D: show line 3 in the form
Bizily Scott Chief Legal Officer 2026-08-17 Sale 10b5-1 −1,635 $12.20 $19,947 8,617 D: show line 4 in the form
Open-market sales · 3,270 sh · avg $12.10 · $39,567

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Bizily Scott Chief Legal Officer 2026-08-13 Option exercise · Stock Option (Right to Buy) 10b5-1 −1,635 61,336 D: show line 5 in the form
Bizily Scott Chief Legal Officer 2026-08-17 Option exercise · Stock Option (Right to Buy) 10b5-1 −1,635 59,701 D: show line 6 in the form
Loading xslF345X06/ownership.xml…